Protara Therapeutics Reports Positive Interim Results for TARA-002 in Phase II ADVANCE-2 Trial for BCG-Naive NMIBC Patients

Protara Therapeutics has released updated interim results for its Phase II ADVANCE-2 trial of TARA-002 in patients with non-muscle invasive bladder cancer. The trial is ongoing and open-label, and the company expects to report further results in the future. The trial is evaluating the safety and efficacy of TARA-002 in patients with BCG-naive non-muscle invasive bladder cancer.